First experience of Russian-manufactured generic nusinersen treatment in pediatric SMA patients

Currently, Russian-manufactured generic products are being actively implemented into the clinical practice in the Russian Federation, including spinal muscular atrophy treatment. This article presents five clinical cases with various types of spinal muscular atrophy treatment with generic Russian nusinersen, both naive and those who had previously received therapy with the reference drug nusinersen and continued therapy with generic nusinersen. The trend in motor activity in patients during treatment, assessed by motor development scales, is presented. In all of 5 described clinical cases both the positive effect and favorable safety profile of the Russian-manufactured generic nusinersen were demonstrated.